TY - JOUR
T1 - Tyrosine kinase inhibitors
T2 - Why does the current process of clinical development not apply to them?
AU - Arteaga, Carlos L.
AU - Baselga, Jose
N1 - Funding Information:
Supported by NCI Grant CA80195 (to C.L.A.), Breast Cancer Specialized Program of Research Excellence (SPORE) Grant P50 CA98131, and Vanderbilt-Ingram Cancer Center Support Grant P30 CA68485, and Spanish Health Ministry “Fondo de Investigacion Sanitaria” Grant 99-0020-01 (to J.B.). We apologize to those colleagues whose work is not referenced because of space constraints or our oversight.
PY - 2004/6
Y1 - 2004/6
N2 - The robust clinical activity of imatinib and trastuzumab for treatment of chronic myeloid leukemia, gastrointestinal stromal tumors, and breast cancer has demonstrated that blocking pathogenic tyrosine kinases can alter the natural history of human tumors. On the other hand, EGF receptor inhibitors have shown overall modest activity. The contrast in the development of these agents implies that both molecular target dependence and patient selection are essential for the successful outcome of this process. We will contrast lessons derived from the development of inhibitors of Abl, c-Kit, HER2/neu (erbB2), and EGFR, highlight successes and limitations in the field, and propose new approaches for clinical development of tyrosine kinase inhibitor therapy.
AB - The robust clinical activity of imatinib and trastuzumab for treatment of chronic myeloid leukemia, gastrointestinal stromal tumors, and breast cancer has demonstrated that blocking pathogenic tyrosine kinases can alter the natural history of human tumors. On the other hand, EGF receptor inhibitors have shown overall modest activity. The contrast in the development of these agents implies that both molecular target dependence and patient selection are essential for the successful outcome of this process. We will contrast lessons derived from the development of inhibitors of Abl, c-Kit, HER2/neu (erbB2), and EGFR, highlight successes and limitations in the field, and propose new approaches for clinical development of tyrosine kinase inhibitor therapy.
UR - http://www.scopus.com/inward/record.url?scp=2942603264&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2942603264&partnerID=8YFLogxK
U2 - 10.1016/j.ccr.2004.05.028
DO - 10.1016/j.ccr.2004.05.028
M3 - Comment/debate
C2 - 15193255
AN - SCOPUS:2942603264
SN - 1535-6108
VL - 5
SP - 525
EP - 531
JO - Cancer Cell
JF - Cancer Cell
IS - 6
ER -